Clinical trials: Refractory Schizophrenia, open to volunteers
Treatment-resistant Schizophrenia
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS).
- Trial name
- NCT07773831
- Testing
- Temporal Interference Stimulation
- Volunteers
- 20 people
- Sponsor
- Zhimin Wang
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Hallucinations, Auditory
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
The INTRUDE trial aims at assessing the efficacy of an fMRI-based neurofeedback procedure on drug-resistant auditory hallucinations.
- Conditions
- Schizophrenia, Hallucinations, Auditory, Hallucinations, Visual
- Trial name
- INTRUDE (NCT04798131)
- Testing
- Active neurofeedback procedure
- Where
- France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
Refractory Auditory Hallucinations, Schizophrenia
RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography
This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations.
- Trial name
- NCT06802939
- Testing
- rTMS
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia Disorders, Schizo Affective Disorder
SEEG-Guided DBS for Schizophrenia
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia.
- Trial name
- NCT07671261
- Testing
- SEEG implantation, Deep brain stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Deep Brain Stimulation
Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders
This is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder…
- Trial name
- NCT06112067
- Testing
- deep brain stimulation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Mental Health Center
Treatment Resistant Schizophrenia
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected…
- Trial name
- HALLUSTIM (NCT06361160)
- Testing
- Active Transcranial Magnetic Stimulation (TMS)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier St Anne
Treatment Resistant Disorders
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia.
- Trial name
- NCT07592611
- Testing
- Medtronic Percept with SensSight Deep Brain Stimulation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Treatment-resistant Schizophrenia
Sequential Treatment Approaches for Treatment-Resistant Schizophrenia
The goal of this study is to optimize treatment strategies for Chinese patients with treatment-resistant schizophrenia (TRS). It will compare two types of treatment: 1.
- Trial name
- STATRS (NCT07918222)
- Testing
- [Phase 1] Clozapine, [Phase 1] Aripiprazole, [Phase 1] Amisulpride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Psychosis, Schizophrenia Disorder
Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and…
- Trial name
- DB RCT (NCT07445620)
- Testing
- Accelerated iTBS, High-Frequency rTMS
- Where
- India
- Volunteers
- 90 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Auditory Hallucination
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication…
- Conditions
- Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
- Trial name
- NCT05299749
- Testing
- stg-rt-fMRI-Neurofeeback
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Boston VA Research Institute, Inc.
Symptom, Cognitive, Schizophrenia
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate
Although antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden.
- Conditions
- Symptom, Cognitive, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT06340789
- Testing
- Sodium Benzoate 2gram/day
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Cheng-Kung University Hospital
Treatment-refractory Schizophrenia, Treatment-resistant Schizophrenia
Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia
Using a randomized controlled design, the project aims to test if cognitive behavioral therapy interventions specifically targeting sleep disorders can significantly lessen the burden of the disrupted sleep in patients with…
- Trial name
- COSTS (NCT06749444)
- Testing
- CBT-I, CBT
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Jimmi Nielsen
Refractory Schizophrenia
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults.
- Trial name
- NCT07369401
- Testing
- Deep Brain Stimulation
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Schizophrenia, Schizo Affective Disorder
Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Trial name
- APTS (NCT04887792)
- Testing
- Acetazolamide
- Where
- 2 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia Negative Type
Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study
The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant…
- Trial name
- NCT07485751
- Testing
- hDFSCs-Exo
- Volunteers
- 15 people
- Sponsor
- Zigong Mental Health Center
Treatment-Refractory Schizophrenia
Deep Brain Stimulation for Psychosis
There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment.
- Trial name
- NCT06257056
- Testing
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bradley Lega
Schizophrenia, Treatment Resistant Schizophrenia
Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant Schizophrenia
Cognitive impairment is a major determinant of disability in schizophrenia. Aerobic exercise improves global cognition in schizophrenia, particularly working memory and attention/vigilance.
- Conditions
- Schizophrenia, Treatment Resistant Schizophrenia, Cognitive Impairment
- Trial name
- TRACE (NCT07404319)
- Testing
- Aerobic Exercise, Stretching/Education Control, Active tDCS
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Kit Wa Chan
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp